TREATS Act
Sponsored By: Representative Norcross
Introduced
Summary
Authorizes telehealth evaluations to satisfy the in-person medical evaluation required to prescribe certain FDA‑approved medications for substance use disorder (SUD). It defines telehealth as a real‑time audio‑only or audio‑plus‑video visit under Social Security Act section 1834(m) and keeps the change subject to Federal and State law.
Show full summary
- People with SUD could receive remote evaluations that count toward the in‑person requirement when clinicians prescribe medications in Schedules III, IV, or V.
- Practitioners, not pharmacists, would be allowed to perform these telehealth evaluations when they follow applicable Federal and State laws.
- The bill requires use of systems that support two‑way, real‑time interactive communication and explicitly permits audio‑only or audio‑plus‑video interactions under the section 1834(m) standard.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Telehealth visits for addiction medicines
If enacted, you could use one telehealth visit as a medical evaluation to get certain addiction treatment medicines. It would apply only to FDA‑approved Schedule III, IV, or V drugs for substance use disorder. You would still need at least one in‑person medical evaluation. Audio‑only phone or audio‑and‑video calls would count if done under federal and state law by a practitioner (not a pharmacist). This would take effect upon enactment.
Sponsors & CoSponsors
Sponsor
Norcross
NJ • D
Cosponsors
Rep. Fitzpatrick, Brian K. [R-PA-1]
PA • R
Sponsored 2/26/2025
Rep. Pettersen, Brittany [D-CO-7]
CO • D
Sponsored 3/4/2025
Connolly
VA • D
Sponsored 3/4/2025
Rep. Tonko, Paul [D-NY-20]
NY • D
Sponsored 3/4/2025
Cohen
TN • D
Sponsored 3/4/2025
Rep. Moulton, Seth [D-MA-6]
MA • D
Sponsored 3/4/2025
Davis (NC)
NC • D
Sponsored 3/4/2025
Rep. Tenney, Claudia [R-NY-24]
NY • R
Sponsored 3/4/2025
Rep. Miller, Carol D. [R-WV-1]
WV • R
Sponsored 3/4/2025
Johnson (GA)
GA • D
Sponsored 3/4/2025
Keating
MA • D
Sponsored 3/4/2025
Rep. Houlahan, Chrissy [D-PA-6]
PA • D
Sponsored 3/4/2025
Rep. Deluzio, Christopher R. [D-PA-17]
PA • D
Sponsored 3/4/2025
Rep. Dingell, Debbie [D-MI-6]
MI • D
Sponsored 3/4/2025
Obernolte
CA • R
Sponsored 3/4/2025
Trahan
MA • D
Sponsored 3/4/2025
Rep. Tokuda, Jill N. [D-HI-2]
HI • D
Sponsored 3/4/2025
Rep. Harder, Josh [D-CA-9]
CA • D
Sponsored 3/4/2025
Jackson (IL)
IL • D
Sponsored 3/4/2025
Rep. Wasserman Schultz, Debbie [D-FL-25]
FL • D
Sponsored 3/4/2025
Rep. Scanlon, Mary Gay [D-PA-5]
PA • D
Sponsored 3/4/2025
Rep. Lawler, Michael [R-NY-17]
NY • R
Sponsored 3/4/2025
Rep. Bacon, Don [R-NE-2]
NE • R
Sponsored 3/4/2025
Barragan
CA • D
Sponsored 3/4/2025
Rep. Thompson, Glenn [R-PA-15]
PA • R
Sponsored 4/29/2025
Rep. Kiggans, Jennifer A. [R-VA-2]
VA • R
Sponsored 9/10/2025
Rep. Balint, Becca [D-VT-At Large]
VT • D
Sponsored 9/15/2025
Liccardo
CA • D
Sponsored 10/8/2025
Craig
MN • D
Sponsored 10/24/2025
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov